Costs of treatment and clinical events for secondary hyperparathyroidism

American Journal of Pharmacy Benefits

Volumn 5, Issue 2, 2013, Pages

  Lee, Andrew ^a   Belozeroff, Vasily ^a   Song, Xue ^b   Diakun, David ^b   Goodman, William ^a  

^a AMGEN INC   (United States)

^b Thomson Reuters   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CINACALCET; DOXERCALCIFEROL; PARICALCITOL; VITAMIN D DERIVATIVE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; FRACTURE; HEALTH CARE COST; HEALTH INSURANCE; HEART FAILURE; HEMODIALYSIS PATIENT; HIP FRACTURE; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PARATHYROIDECTOMY; PERIPHERAL VASCULAR DISEASE; QUALITY OF LIFE; RETROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM; SPINE FRACTURE; UNITED STATES;

EID: 84876541031     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Gabbay E, Meyer KB, Griffith JL, Richardson MM, Miskulin DC. Temporal trends in health-related quality of life among hemodialysis patients in the United States. Clin J Am Soc Nephrol. 2010;5(2):261-267.
2. Malindretos P, Sarafidis P, Lazaridis A, Nikolaidis P. A study of the association of higher parathormone levels with health-related quality of life in hemodialysis patients. Clin Nephrol. 2012;77(3):196-203.
3. Doan QV, Gleeson M, Kim J, Borker R, Griffiths R, Dubois RW. Economic burden of cardiovascular events and fractures among patients with end-stage renal disease. Curr Med Res Opin. 2007;23(7):1561-1569.
4. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208-2218.
5. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68(4):1793-1800.
6. Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2006;70(7):1358-1366.
7. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005;16(6):1788-1793.
8. Kestenbaum B, Andress DL, Schwartz SM, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int. 2004;66(5):2010-2016.
9. Kestenbaum B, Belozeroff V. Mineral metabolism disturbances in patients with chronic kidney disease. Eur J Clin Invest. 2007;37(8):607-622.
10. Raggi P. Coronary-calcium screening to improve risk stratification in primary prevention. J La State Med Soc. 2002;154(6):314-318.
11. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol. 2002;39(4):695-701.
12. Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58(1):396-399.
13. Inaba M, Okuno S, Kumeda Y, Yamakawa T, Ishimura E, Nishizawa Y. Increased incidence of vertebral fracture in older female hemodialyzed patients with type 2 diabetes mellitus. Calcif Tissue Int. 2005;76(4):256-260.
14. Blayney MJ, Pisoni RL, Bragg-Gresham JL, et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int. 2008;74(5):655-663.
15. Messa P, Macário F, Yaqoob M, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008;3(1):36-45.
16. Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm. 2007;13(5):397-411.
17. Shi N, Foley K, Lenhart G, Badamgarav E. Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures. Bone. 2009;45(6):1084-1090.
18. Hallberg I, Bachrach-Lindström M, Hammerby S, Toss G, Ek AC. Health-related quality of life after vertebral or hip fracture: a seven-year follow-up study. BMC Musculoskelet Disord. 2009;10:135.
19. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. http://www.nof.org/hcp/practice/practice-and-clinicalguidelines/ clinicians-guide. Updated 2010. Accessed February 20, 2013.
20. Salaffi F, Cimmino MA, Malavolta N, et al; Italian Multicentre Osteoporotic Fracture Study Group. The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study. J Rheumatol. 2007;34(7):1551-1560.